{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Paraproteinemia&page=17", "query": { "condition": "Paraproteinemia", "page": 17 }, "page_size": 10 }, "pagination": { "page": 17, "page_size": 10, "total_count": 2535, "total_pages": 254, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Paraproteinemia&page=18&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Paraproteinemia&page=16&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T14:02:42.146Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00667329", "title": "Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "2CdA", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 14, "start_date": "1999-07-09", "completion_date": "2022-02-10", "has_results": false, "last_update_posted_date": "2022-03-07", "last_synced_at": "2026-10-22T14:02:42.146Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00667329" }, { "nct_id": "NCT01251575", "title": "Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Acute Lymphoblastic Leukemia", "Adult Acute Myeloid Leukemia", "Adult Diffuse Large B-Cell Lymphoma", "Adult Myelodysplastic Syndrome", "Adult Non-Hodgkin Lymphoma", "Aggressive Non-Hodgkin Lymphoma", "Childhood Acute Lymphoblastic Leukemia", "Childhood Acute Myeloid Leukemia", "Childhood Diffuse Large B-Cell Lymphoma", "Childhood Myelodysplastic Syndrome", "Childhood Non-Hodgkin Lymphoma", "Chronic Lymphocytic Leukemia", "Chronic Lymphocytic Leukemia in Remission", "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Hematopoietic and Lymphoid Cell Neoplasm", "Mantle Cell Lymphoma", "Plasma Cell Myeloma", "Prolymphocytic Leukemia", "Recurrent Chronic Lymphocytic Leukemia", "Refractory Chronic Lymphocytic Leukemia", "T-Cell Prolymphocytic Leukemia", "Waldenstrom Macroglobulinemia", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Hodgkin Lymphoma" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 77, "start_date": "2010-12-01", "completion_date": "2019-02-11", "has_results": true, "last_update_posted_date": "2019-12-09", "last_synced_at": "2026-10-22T14:02:42.146Z", "location_count": 4, "location_summary": "Denver, Colorado • Salt Lake City, Utah • Seattle, Washington", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Salt Lake City", "state": "Utah" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01251575" }, { "nct_id": "NCT00040937", "title": "S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 147, "start_date": "2002-06", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2016-12-08", "last_synced_at": "2026-10-22T14:02:42.146Z", "location_count": 141, "location_summary": "Little Rock, Arkansas • Davis, California • Roseville, California + 85 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Davis", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00040937" }, { "nct_id": "NCT01034553", "title": "Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Aurora A kinase inhibitor MLN8237", "type": "DRUG" }, { "name": "bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2010-02", "completion_date": "2014-11", "has_results": true, "last_update_posted_date": "2016-05-25", "last_synced_at": "2026-10-22T14:02:42.146Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • San Francisco, California • Boston, Massachusetts + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01034553" }, { "nct_id": "NCT01083602", "title": "Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed and Bortezomib Refractory Multiple Myeloma", "Refractory Multiple Myeloma", "Multiple Myeloma in Relapse" ], "interventions": [ { "name": "panobinostat", "type": "DRUG" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2010-06", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2017-12-21", "last_synced_at": "2026-10-22T14:02:42.146Z", "location_count": 13, "location_summary": "Los Angeles, California • Stanford, California • Tampa, Florida + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01083602" }, { "nct_id": "NCT05191472", "title": "Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma", "Multiple Myeloma in Relapse", "Multiple Myeloma, Refractory", "Recurrent Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Alfred Chung, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2022-05-03", "completion_date": "2023-12-31", "has_results": true, "last_update_posted_date": "2025-01-15", "last_synced_at": "2026-10-22T14:02:42.146Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05191472" }, { "nct_id": "NCT00067639", "title": "Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Pegfilgrastim (Neulasta)", "type": "DRUG" }, { "name": "Apheresis", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2003-12", "completion_date": "2007-04", "has_results": false, "last_update_posted_date": "2012-08-01", "last_synced_at": "2026-10-22T14:02:42.146Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00067639" }, { "nct_id": "NCT05650632", "title": "A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Etentamig (ABBV-383)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 210, "start_date": "2023-03-21", "completion_date": "2029-08", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-10-22T14:02:42.146Z", "location_count": 27, "location_summary": "Phoenix, Arizona • Springdale, Arkansas • Aurora, Colorado + 23 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Newark", "state": "Delaware" }, { "city": "Hinsdale", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05650632" }, { "nct_id": "NCT00520130", "title": "Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelodysplastic Syndrome", "Hodgkin's Lymphoma", "Non-Hodgkin's Disease", "Acute Leukemia", "Multiple Myeloma" ], "interventions": [ { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Allogenic stem cell transplant (ASCT)", "type": "DRUG" }, { "name": "Conditioning Chemotherapy", "type": "DRUG" }, { "name": "TMS", "type": "DRUG" }, { "name": "FLAG", "type": "DRUG" }, { "name": "EPOCH-F", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "74 Years", "sex": "ALL", "summary": "18 Years to 74 Years" }, "enrollment_count": 92, "start_date": "2007-10-30", "completion_date": "2018-12-31", "has_results": true, "last_update_posted_date": "2019-03-05", "last_synced_at": "2026-10-22T14:02:42.146Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00520130" }, { "nct_id": "NCT02909036", "title": "Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Amyloidosis" ], "interventions": [ { "name": "Melphalan", "type": "DEVICE" }, { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Autologous Hematopoietic Progenitor Cell Transplant", "type": "PROCEDURE" } ], "intervention_types": [ "DEVICE", "DRUG", "PROCEDURE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 46, "start_date": "2016-09", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-22T14:02:42.146Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02909036" } ] }